Exclusive: RA Capital backs intranasal viral prophylactic with $34M and a plan for Phase 2b

NorthLinks Bio, backed by RA Capital with $34M, is advancing HEX17 — an intranasal broad-spectrum viral prophylactic from Pneumagen — into a global Phase 2b protection study.

Raccontata daendpoints.news